The Top 10 bestselling orphan drugs in the USA in 2017. Celgene's Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion,…

Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government,…

Gianfranco Biliotti, recently appointed General Manager for Alexion Colombia, shares his insights on the particularities of operating in the…

Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses…

Julie O’Neill, Alexion’s EVP for Global Operations highlights Alexion’s establishment of its Global Supply Chain headquarters in Dublin,…

Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the…